Virtual twins for model‐informed precision dosing of clozapine in patients with treatment‐resistant schizophrenia
CPT: Pharmacometrics & Systems Pharmacology · 2024-03 · 13 (3) · 424-436
DOI: 10.1002/psp4.13093 ↗Kurz gefasst
Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 19.01.2024. Verfasst von Sam Mostafa und 8 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Medicine Use and Safety, Monash University, Parkville, Victoria, Australia. Hauptthemen laut MEDLINE: Clozapine, Antipsychotic Agents, Schizophrenia. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Model‐informed precision dosing using virtual twins (MIPD‐VTs) is an emerging strategy to predict target drug concentrations in clinical practice. Using a high virtualization MIPD‐VT approach (Simcyp version 21), we predicted the steady‐state clozapine concentration and clozapine dosage range to achieve a target concentration of 350 to 600 ng/mL in hospitalized patients with treatment‐resistant schizophrenia ( N = 11). We confirmed that high virtualization MIPD‐VT can reasonably predict clozapine concentrations in individual patients with a coefficient of determination ( R 2 ) ranging between 0.29 and 0.60. Importantly, our approach predicted the final dosage range to achieve the desired target clozapine concentrations in 73% of patients. In two thirds of patients treated with fluvoxamine augmentation, steady‐state clozapine concentrations were overpredicted two to four‐fold. This work supports the application of a high virtualization MIPD‐VT approach to inform the titration of clozapine doses in clinical practice. However, refinement is required to improve the prediction of pharmacokinetic drug–drug interactions, particularly with fluvoxamine augmentation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Centre for Medicine Use and Safety, Monash University, Parkville, Victoria, Australia.
- MyDNA Life Australia Limited, Victoria, Australia.
- BC Mental Health and Substance Use Services, BC Psychosis Program, Lower Mainland Pharmacy Services, Vancouver, British Columbia, Canada.
- Certara, Princeton, New Jersey, USA.
- Department of Clinical Pharmacology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
- Department of Psychiatry, Melbourne Neuropsychiatry Centre, University of Melbourne and Melbourne Health, Melbourne, Victoria, Australia.
ORCID-Profile: Sam Mostafa, Reza Rafizadeh, Thomas M Polasek, Chad A Bousman, Amin Rostami-Hodjegan, Robert Stowe, Prescilla Carrion, Carl M J Kirkpatrick
Zitieren
APA
Mostafa, S., Rafizadeh, R., Polasek, T. M., Bousman, C. A., Rostami-Hodjegan, A., Stowe, R., Carrion, P., Sheffield, L. J., & Kirkpatrick, C. M. J. (2024). Virtual twins for model‐informed precision dosing of clozapine in patients with treatment‐resistant schizophrenia. CPT: Pharmacometrics & Systems Pharmacology, 13(3), 424-436. https://doi.org/10.1002/psp4.13093
Vancouver
Mostafa S, Rafizadeh R, Polasek TM, Bousman CA, Rostami-Hodjegan A, Stowe R, et al. Virtual twins for model‐informed precision dosing of clozapine in patients with treatment‐resistant schizophrenia. CPT: Pharmacometrics & Systems Pharmacology. 2024;13(3):424-436. doi:10.1002/psp4.13093
BibTeX
@article{Mostafa2024,
author = {Mostafa, Sam and Rafizadeh, Reza and Polasek, Thomas M and Bousman, Chad A and Rostami-Hodjegan, Amin and Stowe, Robert and Carrion, Prescilla and Sheffield, Leslie J and Kirkpatrick, Carl M J},
title = {Virtual twins for model‐informed precision dosing of clozapine in patients with treatment‐resistant schizophrenia},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2024},
volume = {13},
number = {3},
pages = {424--436},
doi = {10.1002/psp4.13093}
}
EUVIMED